Last reviewed · How we verify
Mixed Salt Amphetamine
At a glance
| Generic name | Mixed Salt Amphetamine |
|---|---|
| Also known as | Adderall Extended Release (XR) |
| Sponsor | The University of Texas Health Science Center, Houston |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine (PHASE4)
- Adaptive Response to Intervention (RTI) for Students With ADHD (PHASE4)
- WAKIX® (Pitolisant) Pregnancy Registry
- Biomarkers of ADHD Treatment Response (PHASE1)
- Treating Parents with ADHD and Their Young Children Via Telehealth: a Hybrid Type I Effectiveness-Implementation Trial (PHASE3)
- Adderall XR and Cognitive Impairment in MS (PHASE2, PHASE3)
- Evaluation of Brain Neurotransmitter Levels in Adults With ADHD, Before and After Stimulant Treatment (NA)
- Neuroimaging Study of Risk Factors for Adolescent Bipolar Disorder (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mixed Salt Amphetamine CI brief — competitive landscape report
- Mixed Salt Amphetamine updates RSS · CI watch RSS
- The University of Texas Health Science Center, Houston portfolio CI